186 related articles for article (PubMed ID: 33089874)
1. Phase I study assessing the mass balance, pharmacokinetics, and excretion of [
Zhou X; Sedarati F; Faller DV; Zhao D; Faessel HM; Chowdhury S; Bolleddula J; Li Y; Venkatakrishnan K; Papai Z
Invest New Drugs; 2021 Apr; 39(2):488-498. PubMed ID: 33089874
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Faessel H; Nemunaitis J; Bauer TM; Lockhart AC; Faller DV; Sedarati F; Zhou X; Venkatakrishnan K; Harvey RD
Br J Clin Pharmacol; 2019 Jul; 85(7):1464-1473. PubMed ID: 30845347
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Zhou X; Vaishampayan U; Mahalingam D; Harvey RD; Chung KY; Sedarati F; Dong C; Faller DV; Venkatakrishnan K; Gupta N
Invest New Drugs; 2022 Oct; 40(5):1042-1050. PubMed ID: 35932388
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM; Berger AJ; Burke K; Mulligan G; Dezube BJ; Harvey RD
Clin Cancer Res; 2016 Feb; 22(4):847-57. PubMed ID: 26423795
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and Disposition of [
Bolleddula J; Chen H; Cohen L; Zhou X; Pusalkar S; Berger A; Sedarati F; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2022 Jul; 50(7):989-997. PubMed ID: 35504658
[TBL] [Abstract][Full Text] [Related]
8. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
[TBL] [Abstract][Full Text] [Related]
9. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
Faessel HM; Mould DR; Zhou X; Faller DV; Sedarati F; Venkatakrishnan K
Br J Clin Pharmacol; 2019 Nov; 85(11):2568-2579. PubMed ID: 31355467
[TBL] [Abstract][Full Text] [Related]
11. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
[TBL] [Abstract][Full Text] [Related]
12. Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors.
Zhou X; Richardson DL; Dowlati A; Goel S; Sahebjam S; Strauss J; Chawla S; Wang D; Mould DR; Samnotra V; Faller DV; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2023 Mar; 12(3):257-266. PubMed ID: 36382849
[TBL] [Abstract][Full Text] [Related]
13. Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine.
Handa H; Cheong JW; Onishi Y; Iida H; Kobayashi Y; Kim HJ; Chiou TJ; Izutsu K; Tsukurov O; Zhou X; Faessel H; Yuan Y; Sedarati F; Faller DV; Kimura A; Wu SJ
J Hematol Oncol; 2022 May; 15(1):56. PubMed ID: 35545778
[TBL] [Abstract][Full Text] [Related]
14. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Zhou X; Friedlander S; Kupperman E; Sedarati F; Kuroda S; Hua Z; Yuan Y; Yamamoto Y; Faller DV; Haikawa K; Nakai K; Bowen S; Dai Y; Venkatakrishnan K
Clin Transl Sci; 2021 May; 14(3):1069-1081. PubMed ID: 33503305
[TBL] [Abstract][Full Text] [Related]
15. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
[TBL] [Abstract][Full Text] [Related]
16. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
[TBL] [Abstract][Full Text] [Related]
17. An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
Sumi H; Inazuka M; Morimoto M; Hibino R; Hashimoto K; Ishikawa T; Kuida K; Smith PG; Yoshida S; Yabuki M
Biochem Biophys Res Commun; 2016 Nov; 480(3):380-386. PubMed ID: 27771247
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
Best S; Lam V; Liu T; Bruss N; Kittai A; Danilova OV; Murray S; Berger A; Pennock ND; Lind EF; Danilov AV
Leukemia; 2021 Jan; 35(1):156-168. PubMed ID: 32203139
[TBL] [Abstract][Full Text] [Related]
19. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
Leclerc GM; Zheng S; Leclerc GJ; DeSalvo J; Swords RT; Barredo JC
Leuk Res; 2016 Nov; 50():1-10. PubMed ID: 27626202
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Qin A; Wells L; Malhotra B; Gadgeel S; Schneider BJ; Ramnath N; Rice JD; Kalemkerian GP
Clin Lung Cancer; 2024 Mar; 25(2):128-134. PubMed ID: 37977950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
